#1 Clinical Trials Search in Europe

Specific Nucleic Acid Sna-Hla I

This article discusses several clinical trials investigating the use of Specific Nucleic Acid SNA-HLA I, a component found in various medications being tested for conditions like genital HPV infections, Epstein-Barr virus infections, herpes simplex virus infections, and non-genital warts. These randomized, placebo-controlled studies aim to evaluate the efficacy and safety of treatments containing this substance for managing these viral infections and their associated symptoms.

Table of Contents

What is SPECIFIC NUCLEIC ACID SNA-HLA I?

SPECIFIC NUCLEIC ACID SNA-HLA I is a novel therapeutic agent being studied for its potential in treating various viral infections. It is also known as SNA-HLA I or SPECIFIC NUCLEIC ACID – HUMAN LEUCOCYTE ANTIGEN TYPE I. This substance belongs to a class of treatments called specific nucleic acids, which are designed to interact with the body’s immune system in targeted ways.[1]

Medical Conditions Treated

Based on the clinical trials data, SPECIFIC NUCLEIC ACID SNA-HLA I is being investigated for its effectiveness in treating several viral infections, including:

  • Human Papillomavirus (HPV) infections: Particularly genital HPV infections that can lead to cervical abnormalities.[1]
  • Epstein-Barr Virus (EBV) infections: Associated with conditions like infectious mononucleosis and chronic fatigue.[2]
  • Herpes Simplex Virus (HSV) infections: Specifically, recurrent orofacial herpes infections (cold sores).[3]
  • Non-genital warts: Caused by certain strains of HPV.[4]

Mechanism of Action

While the exact mechanism of action is not fully detailed in the provided information, we can infer that SPECIFIC NUCLEIC ACID SNA-HLA I likely works by interacting with the body’s immune system. The name suggests it may be designed to mimic or interact with Human Leukocyte Antigen (HLA) type I molecules, which play a crucial role in the immune system’s ability to recognize and respond to virally infected cells.[1]

Clinical Trials and Research

Several clinical trials are currently underway to evaluate the efficacy of SPECIFIC NUCLEIC ACID SNA-HLA I for different viral infections:

  1. HPV Study (PAPION): A randomized, placebo-controlled, double-blind study to evaluate the efficacy of a product containing SNA-HLA I (along with other components) in clearing genital high-risk HPV infections.[1]
  2. EBV Study: A trial investigating the effectiveness of a treatment containing SNA-HLA I in reducing fatigue and other symptoms in patients with EBV infections.[2]
  3. Herpes Study: Research on the efficacy of a product including SNA-HLA I in patients with recurrent orofacial herpes infections.[3]
  4. Warts Study (EVAsION): A study evaluating the effectiveness of treatments containing SNA-HLA I on non-genital warts.[4]

These studies aim to assess various outcomes, including viral clearance rates, symptom reduction, and quality of life improvements for patients.

Administration and Dosage

In the clinical trials, SPECIFIC NUCLEIC ACID SNA-HLA I is administered as part of a combination treatment in the form of granules in capsules to be opened. The medication is typically taken via oromucosal use, which means it’s applied to the mucous membranes of the mouth.[1][2][3][4]

The maximum daily dose in the studies is typically 380 mg, with a maximum total dose of 68.4 g over a 6-month treatment period. However, it’s important to note that these dosages are specific to the clinical trials and may not reflect final recommended dosages if the treatment is approved for general use.[1][2][3][4]

Safety and Side Effects

As with any medical treatment, safety is a primary concern in the clinical trials of SPECIFIC NUCLEIC ACID SNA-HLA I. The studies are monitoring for adverse events (AEs) and serious adverse events (SAEs) that may be related to the treatment.[1][2][3][4]

It’s important to note that patients with severe immune deficiency, those undergoing chemotherapy or radiotherapy, and individuals with certain other health conditions are typically excluded from these trials. This suggests that the treatment may not be suitable for everyone and that careful medical supervision is necessary.[1][2][3][4]

As these studies are ongoing, comprehensive information about potential side effects is not yet available. Patients considering participation in clinical trials or future use of this treatment should discuss potential risks and benefits with their healthcare provider.

Condition Medication Primary Endpoint Study Duration
Genital HPV infections 2LPAPI HR-HPV infection clearance at 12 months 12 months
Epstein-Barr Virus infection 2LEBV and 2LXFS Fatigue severity at 6 months 12 months
Recurrent orofacial herpes 2LHERP Number of recurrent episodes at 12 months 12 months
Non-genital warts 2LVERU JUNIOR and 2LVERU Disappearance of warts at 6 months 9 months (6 months treatment + 3 months follow-up)

FAQ

  • What conditions are being studied using medications containing Specific Nucleic Acid SNA-HLA I? The clinical trials are investigating the use of medications containing Specific Nucleic Acid SNA-HLA I for conditions such as genital HPV infections, Epstein-Barr virus infections, recurrent orofacial herpes infections, and non-genital warts.
  • How long do these clinical trials typically last? The duration of these clinical trials varies, but many of them have a follow-up period of 12 months to assess the long-term effectiveness and safety of the treatments.
  • What is the main goal of these clinical trials? The main goal of these clinical trials is to compare the efficacy of the treatments containing Specific Nucleic Acid SNA-HLA I against placebo in reducing symptoms, clearing infections, or preventing recurrences of the targeted conditions.
  • Are there any common side effects mentioned in these trials? The trials include safety assessments to monitor for adverse events (AEs) and serious adverse events (SAEs). However, specific side effects are not detailed in the provided information. Safety is a secondary objective in most of these studies.
  • Who can participate in these clinical trials? Eligibility criteria vary for each trial, but generally include adults (and in some cases, adolescents) with the specific condition being studied. Participants must meet certain health criteria and be willing to follow the study protocols. Pregnant or breastfeeding women are typically excluded.

Ongoing Clinical Trials on Specific Nucleic Acid Sna-Hla I

  • Study on the Effectiveness of 2LHERP in Reducing Recurrent Cold Sores in Patients with Frequent Outbreaks

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Placebo-controlled: A study design where some participants receive an inactive substance (placebo) instead of the actual treatment, allowing researchers to compare the true effects of the medication being tested.
  • Double-blind: A study method where neither the participants nor the researchers directly involved know who is receiving the actual treatment and who is receiving the placebo, reducing potential bias in the results.
  • Efficacy: The ability of a treatment to produce the desired beneficial effect under ideal circumstances.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Events (SAEs): An adverse event that results in death, is life-threatening, requires hospitalization, causes a significant incapacity, or results in a congenital anomaly or birth defect.
  • HPV: Human Papillomavirus, a common sexually transmitted infection that can cause genital warts and certain types of cancer.
  • Epstein-Barr Virus (EBV): A common virus that can cause infectious mononucleosis and is associated with certain types of cancer.
  • Orofacial herpes: Viral infections caused by herpes simplex virus affecting the mouth, lips, and surrounding areas of the face.
  • Cytology: The study of cells from the body to detect abnormalities or changes that may indicate disease.
  • Asthenia: A condition characterized by weakness or lack of energy.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-2lpapi-with-interferon-alfa-in-clearing-genital-hpv-infections-in-patients/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-2lebv-and-2lxfs-for-reducing-fatigue-in-patients-with-epstein-barr-virus-infection/
  3. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-2lherp-in-reducing-recurrent-cold-sores-in-patients-with-frequent-outbreaks/
  4. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-interferon-alfa-interleukin-1-and-interleukin-2-in-treating-non-genital-warts-in-patients/